ClinicalTrials.gg
CompletedNCT00046176Updated Mar 24, 2020

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

A Phase 3 interventional study of abacavir/lamivudine and abacavir in Infection, Human Immunodeficiency Virus I and HIV Infection, sponsored by ViiV Healthcare. Completed at 56 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-24.

Primary conditionHIV InfectionsRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
HIV Infections
Why
  1. The study's listed conditions name HIV Infections, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing abacavir in HIV Infections — 1 open to participants now, 1 under way, 1 of them phase 3. Abacavir · HIV Infections.

Enrollment
16th of 50
240 · median 78
Started
2002
the only one that year
Phase 3
16 of 57
1 open now
Registered
34th of 57
by date
Lead sponsor
3 of 57
ViiV Healthcare

Among the 57 studies testing abacavir in HIV Infections, this one is the 16th largest by enrollment of the 50 interventional ones that give a count, is the only one that started in 2002, is one of 16 in phase 3, and was the 34th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 57 studies testing abacavir in HIV Infections is open now. Recruiting first, the newest first:

About abacavir

Abacavir: first FDA approval 1998 (ZIAGEN), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing abacavir in HIV Infections, or all of them as a file.
02

Study summary

This study is a 48-week study designed to evaluate the safety and efficacy of a fixed-dose combination tablet administered once-a-day versus the individual tablets administered twice-a-day within 3-drug combination regimens in ART (antiretroviral)-experienced HIV-1 infected patients.

03

Conditions studied

  • Infection, Human Immunodeficiency Virus I
  • HIV Infection

Browse trials for

Keywords

  • HIV-1 Abacavir Lamivudine Antiretroviral-experienced
04

In context

HIV Infections Reclassified

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

This study's enrollment of 240 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently receiving an initial antiretroviral therapy (ART) regimen composed of the drug abacavir (ABC) 300mg twice a day, plus the drug 3TC (lamivudine) 150mg twice a day in combination with either a protease inhibitor or non-nucleoside reductase inhibitor (NNRTI) for at least 24 weeks.
  • NOTE: Subjects who have required a change in initial protease inhibitor (PI) or NNRTI therapy due to intolerance (not treatment failure) are eligible. Subject must be on a stable regimen of the second PI or NNRTI therapy for at least 6 months before enrollment in this study.
  • Plasma -1 RNA less than 400 copies/mL for at least 3 months immediately preceding the screening visit, and at screening.
  • of at least 50 cells/mm3 at screening.
  • Written to participate in the study before participation.
  • Male or female (Females of must have a negative serum pregnancy test at screening and agree to an acceptable method of .)

Exclusion criteria

Exclusion Criteria:

  • History of a CDC Clinical Category C event requiring treatment (not including cutaneous Kaposi's sarcoma) within 45 days of the screening visit. Treatment for the acute event must have been completed at least 30 days before screening.
  • Subject is enrolled in one or more drug studies which may impact RNA suppression.
  • Subject is unable to complete the 48-week dosing period, evaluations and assessments.
  • Subject is pregnant or breastfeeding.
  • History of inflammation of the pancreas or hepatitis within 6 months prior to screening.
  • Subject suffers from a serious medical condition, such as diabetes or heart problem.
  • Pre-existing mental, physical, or substance abuse disorder.
  • History of inflammatory bowel disease or , intestinal ischemia, malabsorption, or other gastrointestinal dysfunction.
  • Abnormal laboratory results within 28 days before the first dose of study medication.
  • Required treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days before screening, or will need these during the study.
  • Subject requires treatment with immunomodulating drugs such as systemic , interleukins, vaccines, or interferons within 28 days prior to screening, or subject has received an HIV-1 immunotherapeutic vaccine within 90 days prior to screening.
  • Asthmatic subjects using inhaled corticosteroids are eligible for enrollment.
  • Subject requires treatment with foscarnet, hydroxyurea or other agents with documented activity against HIV-1 in vitro within 28 days of screening.
  • Subject has a history of allergy to any of the study drugs.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants

Interventions

  • Drugabacavir/lamivudine
  • Also known as: abacavir, abacavir/lamivudine

07

What researchers measure

Primary outcomes

  1. Proportion of non-virologic failures through Week 48. Treatment-limiting adverse events over 48 weeks.

    Time frame: 48 weeks

Secondary outcomes

  1. Viral load response at Week 24 and 48 T-cell count Disease progression Health outcomes Resistance

    Time frame: 48 weeks

08

Study locations

56 sites
  • GSK Investigational Site
    Phoenix, Arizona 85006, United States
  • GSK Investigational Site
    Fountain Valley, California 92708, United States
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    Los Angeles, California 90028, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Sacramento, California 95825, United States
  • GSK Investigational Site
    San Francisco, California 94115-1931, United States
  • GSK Investigational Site
    Torrance, California 90502, United States
  • GSK Investigational Site
    Denver, Colorado 80205, United States
  • GSK Investigational Site
    Denver, Colorado 80220, United States
  • GSK Investigational Site
    Washington, District of Columbia 20007, United States
  • GSK Investigational Site
    Washington, District of Columbia 20009, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33145, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Fort Myers, Florida 33901, United States
  • GSK Investigational Site
    Jacksonville, Florida 32206, United States
  • GSK Investigational Site
    Miami, Florida 33133, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Orlando, Florida 32804, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Plantation, Florida 33317, United States
  • GSK Investigational Site
    Tampa, Florida 33602, United States
  • GSK Investigational Site
    Tampa, Florida 33614, United States
  • GSK Investigational Site
    Atlanta, Georgia 30308, United States
  • GSK Investigational Site
    Atlanta, Georgia 30339, United States
  • GSK Investigational Site
    Augusta, Georgia 30912, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Wichita, Kansas 67214, United States
  • GSK Investigational Site
    Baltimore, Maryland 21201, United States
  • GSK Investigational Site
    Hillsborough, New Jersey 08844, United States
  • GSK Investigational Site
    Somers Point, New Jersey 08244, United States
  • GSK Investigational Site
    New York, New York 10011, United States
  • GSK Investigational Site
    New York, New York 10014, United States
  • GSK Investigational Site
    New York, New York 10019, United States
  • GSK Investigational Site
    Stony Brook, New York 11794, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    Greenville, North Carolina 27858, United States
  • GSK Investigational Site
    Akron, Ohio 44304, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74127, United States
  • GSK Investigational Site
    Hershey, Pennsylvania 17033, United States
  • GSK Investigational Site
    Reading, Pennsylvania 19601, United States
  • GSK Investigational Site
    Columbia, South Carolina 29206-4713, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37916, United States
  • GSK Investigational Site
    Dallas, Texas 75204, United States
  • GSK Investigational Site
    Dallas, Texas 75208, United States
  • GSK Investigational Site
    Dallas, Texas 75219, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Houston, Texas 77004, United States
  • GSK Investigational Site
    Houston, Texas 77027, United States
  • GSK Investigational Site
    Hampton, Virginia 23666, United States
  • GSK Investigational Site
    San Jose, Costa Rica
  • GSK Investigational Site
    Panama City, Panama
  • GSK Investigational Site
    Ponce, 00731, Puerto Rico
  • GSK Investigational Site
    Rio Piedras, 925, Puerto Rico
09

References and documents

Publications

  • ABACAVIR + LAMIVUDINE FIXED DOSE COMBINATION TABLET ONCE DAILY (QD) COMPARED WITH ABACAVIR (ABC) AND LAMIVUDINE (3TC) TWICE DAILY (BID) IN HIV-1 INFECTED SUBJECTS (ESS30008). Hill-Zabala, Christina E. PharmD 1, Sosa, Nestor MD 2, DeJesus, Edwin MD 3, Herrera, Gisella MD, Florance, Allison M. MS , Watson, Maria E. PhD , and Shaefer, Mark S. PharmD (144F), 2005 Annual Meeting of the American College of Clinical Pharmacy, San Francisco, CA; USA, 10/23/2005
  • EFFICACY AND SAFETY OF A ONCE DAILY FIXED-DOSE COMBINATION OF ABACAVIR/LAMIVUDINE (ABC/3TC) [FDC ] VERSUS ABC TWICE DAILY AND 3TC ONCE DAILY AS SEPARATE ENTITIES [SE] IN ART-EXPERIENCED HIV-1 INFECTED SUBJECTS (CAL30001): 48 WEEK DATA. Clumeck, N., LaMarca, A., Fu, K., Gordon, D., Craig, C., Zhao, H., Paes, D., and Scott, T. (WePe6.3C13), 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro; Brazil, 7/24/2005
  • Sosa N, DeJesus E, Hill-Zabala C, et al. Abacavir + lamivudine (ABC/3TC) fixed-dose combination tablet once-daily compared with abacavir and lamivudine twice-daily in HIV-1-infected subjects over 48 weeks (ESS30008). 2th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 22-25, 2005. [poster 572]
  • PATIENT SATISFACTION WITH ABACAVIR (ABC)-LAMIVUDINE (3TC) FIXED DOSE COMBINATION (FDC) TABLET ONCE DAILY (QD) COMPARED WITH ABC AND 3TC TWICE DAILY (BID) IN HIV-1 INFECTED PATIENTS (ESS30008). Hill-Zabala, Christina E. PharmD , Watson, Maria E. PhD , Sosa, Nestor MD , DeJesus, Edwin MD , and Florance, Allison M. MS (145E), 2005 Annual Meeting of the American College of Clinical Pharmacy, San Francisco, CA; USA, 10/23/2005
  • Sosa N, Hill-Zabala C, Dejesus E, Herrera G, Florance A, Watson M, Vavro C, Shaefer M. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):422-7. doi: 10.1097/01.qai.0000184859.24071.bd. PubMed 16280696 ↗
  • Sosa N, DeJesus E, Hill-Zabala C, et al. Abacavir + lamivudine (ABC/3TC) fixed-dose combination tablet once-daily compared with abacavir and lamivudine twice-daily in HIV-1-infected subjects (ESS30008). 7th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 14-18, 2004 . [poster P45]
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2002 to primary completion in May 2004, 20 months.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 20 months is close to that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2002
First posted
Sep 23, 2002
StartActual
Aug 26, 2002
Primary completionActual
May 17, 2004
CompletionActual
May 17, 2004
Last update
Mar 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00046176
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Sep 23, 2002
Start date
Aug 26, 2002
Primary completion
May 17, 2004
Completion
May 17, 2004
Last update
Mar 24, 2020

Study contacts

GSK Clinical Trials, MD
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abacavir · Lamivudine

Start the discussion